Eyeworld

FEB 2012

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/78719

Contents of this Issue

Navigation

Page 12 of 111

February 2012 Dry Eye Lid Squeezers The AcuFocus KAMRA inlay for the treatment of presbyopia Source: Perry S. Binder, M.D. clinical studies over the past 7 years have led to the optimal depth place- ment in the cornea. Early studies demonstrated that shallow place- ment of the inlay has the potential to create some stress on the cornea, causing corneal shape change and thinning and ultimately resulting in an explant of the inlay. After per- forming a series of studies we also found that if the inlay was im- planted too deeply, we had much lower visual recovery. The inlay should be implanted at an optimal depth of 200 microns. When kept at this depth, the cornea tolerates the inlay very well. Development in other areas of ophthalmology has also aided in the advances in the corneal inlay proce- dure. The femtosecond laser allows surgeons to program what they want, and then it is executed with precision. This permits them to not only control the depth, but also the configuration of the incision. The precision of the laser allows us to make pockets at certain locations in the cornea, aiding with centration. Another new technology now in use, the AcuTarget System, provides surgeons with real-time inlay place- ment guidance within 100 microns of the intended placement location, as well as objective placement assess- ment post-op. This surgical aid has the potential to reduce procedure time, resulting in quieter eyes in the immediate post-op period. In addition to historical data dating back to the 1960s, in-depth, international, multicenter clinical trials have provided evidence of the safety and efficacy of the KAMRA corneal inlay. With the transition from an investigational product for many years to a commercially avail- able product outside of the U.S., there are now over 8,000 inlays implanted in Japan, Australia/New Zealand, Europe, the Middle East, and South America, without any corneal thinnings and with good patient satisfaction. EW References 1. Barraquer JI. Queratoplatica Refractiva. Estudios e informaciones Oftalmologicas. 1949;2:10. 2. Deg JK, Binder PS. Histopathology and clini- cal behavior of polysulfone intracorneal im- plants in the baboon model. Polysulfone lens implants. Ophthalmology. 1988;95:506-515. 3. Alió JL, Mulet ME, Zapata LF, Vidal MT, De Rojas V, Javaloy J. Intracorneal inlay compli- cated by intrastromal epithelial opacification. Arch Ophthalmol. 2004;122:1441-1446. 4. Choyce P. The present status of intracam- eral and intracorneal implants. Can J Ophth.1968;3:295-311. Editors' note: Dr. Durrie has financial interests with AcuFocus. Contact information Durrie: 913-491-3330, ddurrie@durrievision.com 3360 Scherer Drive, Suite B, St. Petersburg, FL 33716 s4EL s&AX %MAIL )NFO 2HEIN-EDICAL COMs7EBSITE WWW 2HEIN-EDICAL COM $EVELOPED)N#OORDINATION7ITH3TEVEN, -ASKIN - $ $EVELOPED)N#OORDINATION7ITH$AVID2 (ARDTEN - $ 2HEIN-EDICAL3TYLIZED%YE 1321 Rev.A BABB Meibum Expression Is Recommended As A Subsequent Procedure To Meibomian Gland Probing, Insuring The Patency Of Meibomian Glands. Call 800-637-4346 For More Information. 8-01717: Hardten Eyelid Compression Forceps** l e r 8-01716: Maskin™ Meibum Expressor* m M e i R b o l u s E C l o x p r e s e s s d i o n

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - FEB 2012